CHICAGO (GenomeWeb) – A clinical trial of a PARP inhibitor in metastatic pancreatic cancer patients has yielded "practice changing" results, according to some oncologists, and will likely lead to more widespread testing for germline mutations in the inherited cancer risk genes BRCA1 and BRCA2.
Lynparza Delays Progression in Metastatic Pancreatic Cancer Patients With Germline BRCA Mutations
Premium
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.